Kymera Therapeutics, Inc. (KYMR) Down 4.5% — Should I Secure What's Left?
Kymera Therapeutics, Inc. (KYMR) is losing ground this Thursday, last changing hands at $128.71 on the NASDAQ, a $6.13 decline from the prior close of $134.84. The pullback comes just two sessions after the stock set its 52-week high of $142.92 on November 10, 2026, and leaves shares about 9.9% below that peak. Even after today's slide, KYMR trades more than twice its 52-week low of $60.25, so the decline trims a strong run rather than reversing it.
Turnover has been light so far, with roughly 78,716 shares traded against a 90-day average of about 775,944. The session is still open, and at this pace participation is well below a typical day.
Why Kymera Therapeutics, Inc. Price is Moving Lower
Broad selling across biotechnology industry is the clearest driver of today's decline. The SPDR S&P Biotech ETF (XBI) was down 3.63% at 10:26 a.m. ET, close to KYMR's own drop. Clinical-stage and growth-oriented names have taken the brunt. Moderna, Inc. (MRNA) is down 4.35%, almost matching Kymera, and Revolution Medicines, Inc. (RVMD) has lost 2.34%. The wider tape adds to the pressure. A Reuters' market review described continued caution following a selloff in technology and AI shares, with crowded positions being unwound. Investors are trimming exposure to high-multiple names, and a biotech that just hit a 52-week high two days ago is an easy candidate for profit-taking.
The company's own fundamentals give buyers little reason to step in on weakness. Kymera's Q3 results, released on October 29, missed expectations on both lines. The loss per share was $1.32 against a $1.26 consensus, and revenue of $1.35 million fell well short of the $3.28 million analysts expected. The net loss widened to $132.0 million from $82.2 million a year earlier, and collaboration revenue dropped to zero from $2.8 million. That leaves the valuation resting almost entirely on clinical progress rather than income.
The pipeline has given investors reasons for optimism, but the biggest test is still ahead. Kymera reported positive Phase 1 results for KT-579, its oral IRF5 degrader. The more important readout is KT-621, with topline data from its atopic dermatitis trial expected by year-end 2026. With that binary event weeks away and the stock already priced near its highs, holders appear willing to lock in gains when sector sentiment turns.
What is the Kymera Therapeutics, Inc. Rating - Should I Sell?
Weiss Ratings assigns KYMR a D- rating. The rating was upgraded on 4/25/2024. Current recommendation is Sell. The upgrade more than two years ago did not lift the stock out of Sell territory. The D- reflects a company whose market value has run well ahead of its operating results.
Kymera's strengths sit in its balance sheet and its share price performance. The Excellent rating on the Solvency Index rests on $1.646 billion in cash and investments as of September 30, 2026, which management says should fund operations into 2029. For a clinical-stage developer, that runway means the KT-621 and KT-579 programs can advance without near-term dilution hanging over the stock. The Excellent Total Return Index rating reflects what shareholders have actually experienced: a climb from a 52-week low of $60.25 to a high of $142.92 this week, a gain few names in the sector can match.
Where the picture turns sharply is in the operating business. The Very Weak rating on the Growth Index reflects a quarter in which revenue missed consensus by more than half and collaboration revenue went to zero. Growth for Kymera is still measured in trial milestones rather than sales. The Very Weak Efficiency Index tells the same story from the cost side. A -341.78% profit margin and a net loss that widened to $132.0 million show that spending is rising faster than any offsetting income. Trailing EPS of -$3.62 and a forward P/E of -37.25 confirm that profitability is not in view. The Weak Volatility Index is visible in today's session. A stock that more than doubled off its lows can surrender 4.55% in a single morning on sector-wide biotech selling, and the year-end KT-621 readout carries the potential for a much larger move in either direction.
Within the Health Care sector, Kymera is on par with Moderna, Inc. (MRNA, D-), Revolution Medicines, Inc. (RVMD, D-), and Natera, Inc. (NTRA, D-). It trails IQVIA Holdings Inc. (IQV, D+) and Zoetis Inc. (ZTS, D+), whose more established revenue bases support a slightly better risk/reward profile in Weiss's framework, though both still carry Sell recommendations.
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. (KYMR) is a clinical-stage biopharmaceutical company in the Health Care sector. Incorporated in 2015 and headquartered in Watertown, Massachusetts, Kymera develops small-molecule therapeutics that selectively degrade disease-causing proteins. Rather than simply inhibiting a target, its drugs harness the body's own protein degradation system to eliminate the target. This targeted protein degradation approach is designed to reach disease drivers that traditional small molecules have struggled to address.
The lead program is KT-621, an oral STAT6 degrader in Phase 2b development for moderate to severe atopic dermatitis. Kymera is also pursuing KT-621 in asthma, COPD, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, prurigo nodularis, and bullous pemphigoid. An oral pill acting on the STAT6 pathway could compete directly with injectable biologics in these markets. KT-579 is an oral IRF5 degrader in Phase 1 for autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, systemic sclerosis, and dermatomyositis. The IRAK4 program, KT-485/SAR447971, is in Phase 2 for immunology and inflammation indications such as hidradenitis suppurativa and atopic dermatitis. A cyclin-dependent kinase 2 (CDK2) program gives the company oncology exposure, with potential in breast cancer and other solid tumors.
Kymera's strategic alliance with Sanofi S.A. covers the development of IRAK4-targeting drug candidates outside oncology and immuno-oncology. The partnership lends outside validation to the platform and spreads development risk on that program. The company's competitive position rests on its degrader discovery engine and its focus on oral alternatives in immunology markets dominated by injectables. Still, every product remains in clinical development, so commercial value depends on trial outcomes and regulatory approval.
Investor Outlook
Kymera Therapeutics, Inc. (KYMR) carries a Weiss Rating of D- (Sell). A strong cash position and a stock that has more than doubled off its lows still do not offset deep operating losses and high volatility heading into a pivotal readout. Investors should watch the KT-621 atopic dermatitis topline data expected by year-end 2026, along with any shift in biotech sector sentiment, which drove today's decline. See full rankings of all D- rated Health Care stocks inside the Weiss Stock Screener.
--